Drug Database
PI

piroxicam (piroxicam, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · PTGS1 · 小分子

什么是 piroxicam?

piroxicam 是一种小分子,由Douglas Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名piroxicam, Douglas
公司Douglas Pharmaceuticals Limited
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

piroxicam 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

piroxicam 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Hepatobiliary disordersHepatitis✓ Approved

相关研究文献

PubMedTherapeutic advances in musculoskeletal disease2026-11-15

Ultrasound-mediated cavitation of microbubble-infused dressings increases the therapeutic efficacy of piroxicam gel for hand arthritis: An intraindividual randomized controlled trial.

Lai Kuo-Lung KL, Liao Ai-Ho AH, Li Pai-Chi PC

Combining ultrasound (US) with microbubbles (MBs) increases epidermal permeability and thus facilitates the transfer of drugs into deeper tissues. To investigate the efficacy of combining US-mediated MB cavitation with piroxicam gel for hand arthritis. A single-center, open-label, intraindividual randomized controlled trial. Fifty-two adult patients (mean age 55.0 years; 76.9% females) with hand arthritis in at least three symptomatic joints participated in this study. Three affected joints in each patient were randomly assigned to one of three groups: MB/US group, US group, and control group. The MB/US group received US (1 MHz at 0.49 W/cm2 for 3 minutes) along with an MB-infused dressing immediately followed by piroxicam gel application (1%, 0.5-1 g) on days 1, 3, and 5; the US group received US along with pure gel application immediately followed by piroxicam gel application; and the control group received only piroxicam gel application. Assessments were performed before and after treatment using the pain visual analogue scale (VAS) score, the synovial hypertrophy (SH) area on B-mode images, and synovial vascularity in conventional and ultrafast power Doppler (PD) imaging. The therapeutic response was determined by the pain VAS score, B-mode imaging, and PD imaging. The pain VAS score was significantly lower in the MB/US and US groups than in the control group. The SH area improved in 78.8%, 59.6%, and 53.8% of cases in the MB/US, US, and control groups, respectively, while the synovial vascularity improved in 61.5%, 50.0%, and 51.9%, and the therapeutic response rates were 75.0%, 61.5%, and 53.8%, with MB/US showing a significant improvement over control (p = 0.024). US-mediated cavitation of an MB-infused dressing enhances drug delivery and may improve the therapeutic response for hand arthritis, with no adverse events.

PMID 43034546
阅读全文 →
PubMedThe journal of vascular access2026-11-11

Comparative short-term effects of topical piroxicam gel, diclofenac gel, and EMLA cream on pain reduction during intravenous cannulation: A randomized clinical trial.

Amini Nazanin N, Mohammadi Elham E, Babaei Parvin P, Modir Hesameddin H et al.

Intravenous (IV) cannulation is a common invasive procedure associated with pain and discomfort. This study compared the short-term effects of topical Piroxicam gel, Diclofenac gel, and EMLA cream on pain during IV cannulation. This participant- and outcome assessor-blinded randomized clinical trial included 123 hospitalized patients randomly allocated to three equal groups receiving topical Diclofenac gel, Piroxicam gel, or EMLA cream (n = 41/group). Pain intensity was assessed using the Visual Analogue Scale immediately after cannulation and at 5, 10, 15, 30, and 45 min. Data were analyzed using linear mixed-effects models, with Kruskal-Wallis/Dunn and Friedman tests performed as sensitivity analyses. Categorical variables were analyzed using Chi-square or Fisher's exact tests. Baseline characteristics were comparable among groups (all p > .05). The linear mixed-effects model showed significant effects of treatment group (p = .002), time (p < .001), and treatment-by-time interaction (p < .001). Bonferroni-adjusted pairwise comparisons showed lower pain intensity in the Diclofenac and EMLA groups than in the Piroxicam group immediately after cannulation and at 5 min; no significant pairwise differences were observed from 10 to 45 min. Sensitivity analyses supported the overall temporal decline in pain but showed some differences in individual pairwise comparisons. No serious adverse events were reported. Pain intensity declined substantially over time in all groups. In the primary analysis, Diclofenac and EMLA were associated with lower early pain intensity than Piroxicam, although some pairwise findings were sensitive to the analytical approach. Because no placebo control was included, findings should be interpreted as relative rather than absolute treatment effects. The trial was prospectively registered with the Iranian Registry of Clinical Trials (IRCT) under registration number IRCT20180107038251N8 on June 12, 2023 (1402/03/22), prior to the initiation of participant recruitment in October 2025. Available at: https://www.irct.ir/search/result?query=IRCT20180107038251N8.

PMID 43012328
阅读全文 →
PubMedEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2026-10-29

Impact of phosphate buffer strength and unbuffered water on ionizable drug powder dissolution.

Patel Roshni P RP, Polli James E JE

We are unaware of prior reports of the dependence of drug powder dissolution on buffer strength. The objective was to assess the effect of 5, 10, 50, and 100 mM sodium phosphate concentration on in vitro particle dissolution of ionizable drugs. Three weakly acidic drugs (naproxen, piroxicam, and phenytoin) and one weakly basic drug (dipyridamole) were studied at different pH conditions. Dissolution was conducted using USP Apparatus II with a mini-paddle at 37 °C in 100 mL media. Overall, the effect on dissolution profile was modest, with the largest effect generally being between 5 mM phosphate and zero phosphate (i.e., unbuffered water). Hence, a secondary objective was to predict the dissolution of the four ionizable drugs into unbuffered water, as well as for ibuprofen, ketoprofen, indomethacin, haloperidol, and meloxicam. Predictions anticipated slower ionizable drug dissolution into unbuffered water. Overall, dissolution predictions into buffer were better using the transient pH film model that accounts for the changing solid-liquid interfacial pH during dissolution, than for the conventional z-factor film model.

PMID 42957101
阅读全文 →
PubMedJournal of ethnopharmacology2026-10-13

Artemisia vulgaris and sabinene ameliorate gastric ulceration and its recurrence through modulation of acid secretion, oxidative stress, and inflammatory cytokines: an in vivo and in silico study.

Borba Ana Laura Tomaselli ALT, Freschi Khetlyn K, Miorando Daniela D, Maccagnan Juliana Cristina JC et al.

Artemisia vulgaris L., popularly known as mugwort, is traditionally used to treat gastric disturbances, yet the mechanistic basis of its antiulcer effects is largely unexplored. The study evaluated the gastroprotective, healing, and anti-recurrence effects of the hydroalcoholic extract of A. vulgaris (HEAv) and its constituent sabinene, and their underlying pharmacological mechanisms. Phytochemical analysis of HEAv used LC-MS, LC-MS/MS, and LC-ESI-IT-MSn. Gastroprotective activity of HEAv (3, 10, or 30 mg/kg) and sabinene (3 mg/kg) was assessed in ethanol- and piroxicam-induced ulcers, beyond pyloric ligation. Healing and recurrence were assessed via acetic acid-induced and IL-1β-triggered ulcers, the latter monitored by ultrasonography. Oxidative stress, inflammatory markers, histology, network pharmacology, and molecular docking/dynamics were evaluated, along with acute toxicity in mice. Chemical analysis identified 36 compounds in HEAv, predominantly phenolics and flavonoids. HEAv and sabinene showed gastroprotective effects, corroborated by mucosal protection and modulation of oxidative stress and inflammatory parameters. In addition, HEAv increased gastric pH, compared to omeprazole. Moreover, HEAv and sabinene reduced ulceration in both the healing and recurrence models, accompanied by increased GSH and CAT activity, and reduced LPO, MPO, and pro-inflammatory cytokines (IL-6 and IL-17A). No acute toxicity was observed. Network pharmacology identified inflammatory signaling as a key target of HEAv constituents, and docking and dynamic molecular assays confirmed favorable, stable interactions between phenolic compounds and sabinene with H+/K+-ATPase and IKKβ, supported by favorable MM-PBSA/MM-GBSA binding energies. HEAv and sabinene exert gastroprotective and healing effects by modulating acid secretion, oxidative stress, and inflammatory cytokines, as suggested by in silico analyses. Nonetheless, further studies are warranted to validate the predicted molecular targets and to elucidate additional pharmacological pathways.

PMID 42869396
阅读全文 →
PubMedCancer biology & therapy2026-10-08

Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology.

Hunsu Victoria O VO, Facey Caroline O B COB, Opdenaker Lynn M LM, Boman Bruce M BM

Our Goal is to sensitize human colorectal cancer (CRC) to the differentiation-inducing effects of retinoic acid (RA) agents by suppressing WNT signaling. Previously, we reported that the WNT and RA pathways are functionally linked, and in CRC, APC mutation generates a WNT:RA imbalance leading to incomplete differentiation and stem cell (SC) overpopulation. Hypothesis: Therapeutically inhibiting WNT signaling enhances the ability of retinoid agents to induce growth suppression and differentiation. We tested drug combinations of: (1) anti-WNT agents (Sulindac & Piroxicam) that produce anti-tumor activity in humans and animals harboring germline APC mutations, with (2) RA agents (All-trans-RA, 9-cis RA) and RA metabolism blocking agent (CYP26A1 inhibitors Liarozole and Talarozole), which inhibit proliferation and induce differentiation of CRC cell lines. Results: The combined effect of anti-WNT agents and RA drugs shows additive or synergistic responses in CRC cell lines compared to single agents. Drug combinations decrease the proportion of aldehyde dehydrogenase-positive SCs and increase neuroendocrine cell differentiation in CRC cells that show a synergistic response to treatment. NanoString profiling shows that therapeutically decreasing WNT signaling in CRC cells significantly changes the effect of RA signaling on gene expression. Treating human CRC organoid cultures and PDX mouse models with WNT:RA-based drug combinations led to greater anti-tumor activity as compared to individual agents. Conclusion: Inhibiting WNT signaling effectively sensitizes CRC cells to the anti-tumor effects of retinoids. These findings have important clinical significance for designing new drug combinations against CRC.

PMID 42845214
阅读全文 →
PubMedBMC chemistry2026-09-27

Holistically benchmarked optimization-assisted green spectrophotometric-chemometric approach for simultaneous determination of piroxicam and venlafaxine in pharmaceutical formulations and spiked human plasma.

Alsfouk Bshra A BA, Al-Khatee Lateefa A LA, Al Kamaly Omkulthom O, Tantawy Mahmoud A MA et al.

The recent clinical introduction of the piroxicam (PIR) and venlafaxine hydrochloride (VEN) combination has highlighted the need for analytical methodologies capable of simultaneously quantifying both drugs while minimizing the environmental burden of routine pharmaceutical analysis. To date, only a chromatographic method has been reported for this purpose, which is associated with relatively high organic solvent consumption, greater instrumental complexity, and increased energy requirements. A green UV spectrophotometric platform integrated with chemometric modeling was therefore established for the concurrent determination of PIR and VEN in pharmaceutical formulations and as a proof-of-concept application to spiked human plasma. Spectral measurements were performed using a water-ethanol (1:1, v/v) solvent system, whereas methanol was employed solely for plasma protein precipitation. Experimental design efficiency was enhanced by combining Brereton's multilevel calibration design with a Maximin Distance Design (MMD) for validation sample selection, enabling representative calibration and validation datasets to be generated with a reduced number of experimental mixtures. Severe spectral overlap between the two analytes was effectively resolved using six well-established chemometric approaches: CLS, PCR, PLS, GA-PLS, FA-PLS, and MCR-ALS. Among the investigated models, MCR-ALS showed the best overall numerical performance, achieving correlation coefficients of up to 0.9998 for pharmaceutical formulations and 0.9996 for spiked human plasma. The corresponding limits of detection were 0.125 and 0.029 µg mL⁻¹ for VEN and PIR, respectively, in pharmaceutical formulations, and 0.245 and 0.058 µg mL⁻¹ in spiked human plasma. Across the investigated concentration ranges, the proposed method also exhibited satisfactory accuracy and precision. The sustainability performance of the analytical platform was evaluated using multiple complementary metrics, with the pharmaceutical assay compared with the previously reported chromatographic procedure according to the evaluated criteria. The proposed pharmaceutical spectrophotometric assay showed a more favorable sustainability profile according to the evaluated criteria, including environmental and practical applicability dimensions. The application to spiked human plasma provided a proof-of-concept assessment of matrix applicability. Nevertheless, additional investigations involving incurred clinical specimens and full bioanalytical validation are required before the methodology can be considered suitable for routine clinical practice or pharmacokinetic studies.

PMID 42800863
阅读全文 →

注册免费账户还可查看另外 3341 篇文献

免费注册查看全部文献 →

了解更多piroxicam